查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2146872

甲型肝炎去活化疫苗市場－2026年至2032年全球市場預測

Hepatitis A Inactivated Vaccine Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，甲型肝炎去活化疫苗市場規模將達到 137,642 億美元，複合年成長率為 8.61%。

主要市場統計數據
基準年 2025 7.7193億美元
預計年份：2026年 8.199億美元
預測年份 2032 1,376,420,000 美元
複合年成長率 (%) 8.61%

去活化甲型肝炎疫苗：執行摘要

甲型肝炎去活化疫苗用於預防甲型肝炎病毒感染。甲型肝炎病毒是一種經由口腔或糞口途徑傳播的病原體，可透過受污染的食物或水，或密切的身體接觸傳播。疫苗接種在公共衛生領域的角色因地區而異，取決於流行病狀況、衛生條件、旅行模式、疫情歷史、免疫政策以及醫療保健服務的可近性等因素。本概要著重於基於證據的策略考量，不涉及市場估算、預測、佔有率、展望或公司特定分析。

公共衛生優先事項正在改變疫苗的接種方式。

目前的情況正從針對旅行者的孤立疫苗接種轉向更廣泛的、基於風險的預防措施。常規兒童免疫接種、高風險族群疫苗接種、疫情應變、職業和設施項目以及旅行者保護正日益成為相互補充的工具。甲型肝炎發病率、水和衛生基礎設施以及成人免疫接種實踐方面持續存在的差異仍然影響著政策制定。供應的連續性、明確的目標人群指導指南、冷鏈的可靠性以及疫情期間的快速協調仍然是核心的行動要求。

人工智慧增強了監控和專案實施能力。

人工智慧 (AI) 可以透過改善對病例報告、檢測結果、地理叢集、疫苗接種記錄和環境指標的分析，幫助預防甲型肝炎。預測工具可以幫助公共衛生團隊識別異常感染模式、確定調查優先順序並進行有針對性的風險溝通。在免疫接種工作中，人工智慧可以幫助最佳化預約安排、實施提醒系統、管理庫存並提高記錄品質。這些應用需要具有代表性的資料、隱私保護、臨床檢驗、透明的管治以及人工審核，因為偏差或不完整的記錄會導致資源錯配和不平等。

區域差異會影響預防和應對策略。

在北美，常規或基於風險的免疫接種與強力的監測、旅行者健康服務和疫情應對相結合，但免疫接種的可及性和成人疫苗接種率可能因地區和人口而異。拉丁美洲的優先事項包括保護受衛生條件不均影響的兒童和社區、應對疫情以及維持可靠的免疫系統。在歐洲，各國的免疫接種計畫、旅行模式和高風險族群疫苗接種方法各不相同。在中東，必須關注人口流動、朝聖和大規模集會場所、糧食和水安全以及疫情防範。在非洲，由於地方性疾病盛行率、衛生條件、醫療衛生系統能力和疫苗可近性有顯著差異，綜合預防措施尤其重要。亞太地區的流行病學情況極為複雜，需要協調常規免疫接種計畫、旅客免疫接種、疫情控制以及改善水和衛生條件。

多邊集團的政策協調與實施

東協合作涉及跨境監測、旅行、疫情資訊共用以及流行病學狀況不同的國家之間的免疫接種服務。金磚國家成員國可以在生產能力、採購韌性、監測和調查方面合作，同時也要認知到各國免疫規劃之間存在顯著差異。歐盟受惠於協調的衛生安全機制，但免疫接種的安排和實施仍主要由各成員國負責。七國集團的協調涉及監測標準、緊急準備、衛生系統韌性以及對全球免疫工作的支持。海灣合作理事會成員國必須考慮人員流動性高、日本僑民、朝聖相關旅行、集中式醫療服務等因素。北約的重要性主要體現在保護部隊健康、確保作戰準備、提供部署醫療以及保障基本免疫服務的連續性。

每個國家都需要根據自身俱體情況制定獨特的疫苗接種方案。

澳洲優先考慮常規兒童免疫接種、旅客健康、疫情管理以及在地理位置分散的社區提供醫療服務。巴西將國家免疫基礎設施與衛生、監測和疫情風險的區域差異結合。加拿大必須解決各省和地區之間的差異、旅行者疫苗接種、偏遠地區的醫療服務以及疫情應對問題。中國的做法體現了其龐大的人口、區域多樣性、常規預防以及對食源性和水源傳播途徑的控制。法國、德國、義大利和西班牙正在平衡國家指南、歐洲內部旅行、基於風險的免疫接種和區域感染疾病防範。印度的優先事項包括改善衛生條件、加強監測、保護兒童和高危險群以及在不同環境下提供公平的服務。日本和韓國在其先進的醫療保健系統中整合了旅遊相關預防措施、公共衛生監測和國家指南。墨西哥結合了常規預防措施和針對性預防措施，同時也考慮了區域差異和旅行相關感染風險。俄羅斯的計劃必須考慮到區域差異、醫療保健服務可近性和疫情監測。英國強調國家免疫指南、旅行健康管理、高危險群保護和快速的本地應對措施。美國則著重於常規的、基於風險的建議、旅行疫苗接種、疫情介入和跨轄區公共衛生協調。

提高甲型肝炎疫苗有效性的指導措施

產業和公共衛生領導者應根據​​當地流行病學情況調整產品供應、證據產生和供應鏈，而不是採用一刀切的模式。優先事項包括提高供需透明度、支援冷鍊和庫存管理實務、簡化資格和完成接種的指導，以及與衛生部門合作進行疫情防控工作。項目應將疫苗接種與安全飲用水、衛生設施、食品安全措施、檢測、病例調查和風險溝通結合。領導者也應衡量服務不足人口的疫苗接種率和完成率，評估實際效果，建立負責任的人工智慧管治，並保持安全資訊的透明性。跨境合作對於旅行路線、移民群體、大規模集會和軍事部署尤其重要。

執行摘要的實證調查方法

本概要基於所提供的市場定義（甲型肝炎去活化疫苗），對每個國家、流行病學、免疫政策、疫苗接種體系、區域背景、跨國集團以及特定國家進行了評估。解讀依據既定的公共衛生原則，涵蓋甲型肝炎感染、疫苗接種、監測、疫情控制、衛生及醫療衛生系統實施等面向。本概要有意排除了市場估算和預測、市場規模計算、市場佔有率、預測以及公司特定聲明。每個國家和集團的觀察均作為策略背景呈現，在做出實際決策之前，應對照當前的國家免疫規劃、監管指南、監測報告和當地採購資訊檢驗。

協調一致的預防措施決定著長期效果。

去活化甲型肝炎疫苗的策略重要性更體現在其與預防體系的連結上，而非疫苗接種本身。要取得有效成果，需要根據當地流行病學情況調整免疫接種計劃和基於風險的政策，確保疫苗的可靠獲取，將免疫接種與衛生措施和疫情控制相結合，並負責任地利用監測數據。雖然實施過程需要根據區域、群體和國家差異進行調整，但只有在高品質數據和課責的監督支持下，才能透過人工智慧改進實施。能夠將政策、供應、實施和公共衛生基礎設施有效銜接起來的領導者，將更有能力控制感染的傳播並保護高風險族群。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：甲型肝炎去活化疫苗市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第8章：甲型肝炎去活化疫苗市場：依產品類型分類

  • 多管瓶小瓶
  • 單劑量管瓶

第9章 甲型肝炎去活化疫苗市場：依應用領域分類

  • 暴露後預防
  • 暴露前預防

第10章：甲型肝炎去活化疫苗市場：依最終用戶分類

  • 診所
  • 診斷中心
  • 醫院

第11章：甲型肝炎去活化疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：甲型肝炎去活化疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：甲型肝炎不活化疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 甲型肝炎不活化疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Beijing Institute of Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Changchun Institute of Biological Products Co., Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • GlaxoSmithKline Biologicals SA
  • Merck & Co., Inc.
  • Panacea Biotec Limited
  • PT Bio Farma（Persero）
  • Sanofi Pasteur SA
  • SK Bioscience Co., Ltd.
  • Valneva SE
  • Walvax Biotechnology Co., Ltd.
  • Zhejiang Kangtai Biological Products Co., Ltd.

第17章 主要專家

Product Code: MRR-3D150775E460

The Hepatitis A Inactivated Vaccine Market is projected to grow by USD 1,376.42 million at a CAGR of 8.61% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 771.93 million
Estimated Year [2026] USD 819.90 million
Forecast Year [2032] USD 1,376.42 million
CAGR (%) 8.61%

Hepatitis A Inactivated Vaccine: Executive Summary

Hepatitis A inactivated vaccines are administered to prevent infection by hepatitis A virus, a fecal-oral pathogen associated with contaminated food, water, and close personal contact. The public-health role of vaccination differs by jurisdiction according to endemicity, sanitation, travel patterns, outbreak history, immunization policy, and access to healthcare. This summary focuses on evidence-based strategic considerations without presenting market estimates, shares, forecasts, or company-specific analysis.

Public-Health Priorities Are Reshaping Vaccine Delivery

The landscape is shifting from isolated travel vaccination toward broader risk-based prevention. Routine childhood immunization, vaccination of people at elevated risk of severe disease, outbreak response, occupational and institutional programs, and protection of travelers increasingly operate as complementary channels. Persistent differences in hepatitis A incidence, water and sanitation infrastructure, and adult immunization practices continue to influence policy design. Supply continuity, clear eligibility guidance, cold-chain reliability, and rapid outbreak coordination remain central operational requirements.

Artificial Intelligence Strengthens Surveillance and Program Execution

Artificial intelligence can support hepatitis A prevention by improving analysis of case reports, laboratory results, geographic clustering, vaccination records, and environmental indicators. Predictive tools may help public-health teams identify unusual transmission patterns, prioritize investigations, and target risk communication. In immunization operations, AI can assist with appointment optimization, reminder systems, inventory monitoring, and documentation quality. These applications require representative data, privacy safeguards, clinical validation, transparent governance, and human review because biased or incomplete records can misdirect resources and amplify inequities.

Regional Differences Define Prevention and Access Strategies

North America combines routine or risk-based vaccination with strong surveillance, travel-health services, and outbreak response, while access and adult uptake can vary by jurisdiction and population. Latin America's priorities include protecting children and communities affected by uneven sanitation, addressing outbreaks, and maintaining reliable immunization delivery. Europe reflects differing national schedules, travel patterns, and approaches to vaccinating high-risk groups. The Middle East requires attention to mobility, pilgrimage and mass gathering settings, food and water safety, and outbreak preparedness. Africa faces substantial heterogeneity in endemicity, sanitation, health-system capacity, and vaccine access, making integrated prevention especially important. Asia-Pacific spans highly diverse epidemiological conditions and includes settings where routine programs, travel vaccination, outbreak control, and improvements in water and sanitation must be coordinated.

Multilateral Groups Shape Policy Coordination and Implementation

ASEAN cooperation is relevant to cross-border surveillance, travel, outbreak communication, and immunization access across countries with varied epidemiological conditions. BRICS members can contribute to collaboration on manufacturing capacity, procurement resilience, surveillance, and research while recognizing substantial differences among national programs. The European Union benefits from coordinated health-security mechanisms, although vaccination schedules and delivery remain primarily national responsibilities. G7 coordination is relevant to surveillance standards, emergency preparedness, health-system resilience, and support for global immunization efforts. GCC countries must account for high mobility, expatriate populations, pilgrimage-related travel, and concentrated healthcare delivery. NATO's relevance is primarily through force health protection, operational readiness, deployment medicine, and continuity of essential vaccination services.

Country Contexts Require Distinct Immunization Approaches

Australia emphasizes routine childhood protection, travel health, outbreak management, and access across geographically dispersed communities. Brazil combines national immunization infrastructure with regional variation in sanitation, surveillance, and outbreak risk. Canada must address provincial and territorial differences, travel vaccination, remote access, and outbreak response. China's approach reflects large population scale, regional diversity, routine prevention, and control of food- and water-associated transmission. France, Germany, Italy, and Spain balance national guidance, European travel, risk-based vaccination, and localized outbreak preparedness. India's priorities include sanitation improvement, surveillance, childhood and high-risk-group protection, and equitable delivery across diverse settings. Japan and South Korea integrate travel-related prevention, public-health surveillance, and national guidance within advanced healthcare systems. Mexico combines routine and targeted prevention with attention to regional disparities and travel exposure. Russia's planning must account for regional variation, healthcare access, and outbreak surveillance. The United Kingdom emphasizes national immunization guidance, travel health, risk-group protection, and rapid local response. The United States uses routine and risk-based recommendations, travel vaccination, outbreak interventions, and jurisdictional public-health coordination.

Leadership Actions to Improve Hepatitis A Vaccine Impact

Industry and public-health leaders should align product access, evidence generation, and delivery operations with local epidemiology rather than applying a uniform model. Priorities include strengthening demand and supply visibility, supporting cold-chain and stock-management practices, simplifying eligibility and completion guidance, and partnering with health authorities on outbreak readiness. Programs should combine vaccination with safe water, sanitation, food-safety measures, testing, case investigation, and risk communication. Leaders should also measure coverage and completion across underserved groups, evaluate real-world effectiveness, establish responsible AI governance, and maintain transparent safety communication. Cross-border coordination is particularly important for travel corridors, migrant populations, mass gatherings, and military deployments.

Evidence-Based Methodology for the Executive Summary

This summary uses the supplied market definition-hepatitis A inactivated vaccine-and organizes the assessment across epidemiology, immunization policy, delivery systems, regional conditions, multinational groupings, and named countries. The interpretation is grounded in established public-health principles concerning hepatitis A transmission, vaccination, surveillance, outbreak control, sanitation, and health-system implementation. It deliberately excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Country and group observations are presented as strategic context and should be validated against current national schedules, regulatory guidance, surveillance reports, and local procurement information before operational decisions are made.

Coordinated Prevention Will Determine Long-Term Effectiveness

The strategic importance of inactivated hepatitis A vaccination is closely tied to prevention systems rather than vaccination alone. Effective outcomes depend on matching schedules and risk-based policies to local epidemiology, ensuring dependable access, integrating vaccination with sanitation and outbreak control, and using surveillance data responsibly. Regional, group, and country differences require tailored implementation, while artificial intelligence can improve execution only when supported by high-quality data and accountable oversight. Leaders that connect policy, supply, delivery, and public-health infrastructure will be better positioned to reduce transmission and protect populations at elevated risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hepatitis A Inactivated Vaccine Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adult
  • 7.3. Geriatric
  • 7.4. Pediatric

8. Hepatitis A Inactivated Vaccine Market, by Product Type

  • 8.1. Introduction
  • 8.2. Multi Dose Vial
  • 8.3. Single Dose Vial

9. Hepatitis A Inactivated Vaccine Market, by Application

  • 9.1. Introduction
  • 9.2. Post-Exposure Prophylaxis
  • 9.3. Pre-Exposure Prophylaxis

10. Hepatitis A Inactivated Vaccine Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Diagnostic Centers
  • 10.4. Hospitals

11. Hepatitis A Inactivated Vaccine Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Hepatitis A Inactivated Vaccine Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Hepatitis A Inactivated Vaccine Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Hepatitis A Inactivated Vaccine Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Beijing Institute of Biological Products Co., Ltd.
  • 16.2. Bharat Biotech International Limited
  • 16.3. Changchun Institute of Biological Products Co., Ltd.
  • 16.4. Chongqing Zhifei Biological Products Co., Ltd.
  • 16.5. GlaxoSmithKline Biologicals SA
  • 16.6. Merck & Co., Inc.
  • 16.7. Panacea Biotec Limited
  • 16.8. PT Bio Farma (Persero)
  • 16.9. Sanofi Pasteur SA
  • 16.10. SK Bioscience Co., Ltd.
  • 16.11. Valneva SE
  • 16.12. Walvax Biotechnology Co., Ltd.
  • 16.13. Zhejiang Kangtai Biological Products Co., Ltd.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Hepatitis A Inactivated Vaccine Market, Years Considered for the Study
  • FIGURE 2. Global Hepatitis A Inactivated Vaccine Market, Research Design
  • FIGURE 3. Global Hepatitis A Inactivated Vaccine Market, Research Framework
  • FIGURE 4. Global Hepatitis A Inactivated Vaccine Market, Data Triangulation
  • FIGURE 5. Global Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2025 vs 2032 (%)
  • FIGURE 7. Global Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 9. Global Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Hepatitis A Inactivated Vaccine Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 11. Global Hepatitis A Inactivated Vaccine Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Hepatitis A Inactivated Vaccine Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Hepatitis A Inactivated Vaccine Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 15. Global Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Hepatitis A Inactivated Vaccine Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Hepatitis A Inactivated Vaccine Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Hepatitis A Inactivated Vaccine Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Hepatitis A Inactivated Vaccine Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Hepatitis A Inactivated Vaccine Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Hepatitis A Inactivated Vaccine Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Hepatitis A Inactivated Vaccine Market Segmentation & Coverage
  • TABLE 2. Global Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 4. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 14. Global Multi Dose Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Multi Dose Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Multi Dose Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Single Dose Vial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 18. Global Single Dose Vial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 19. Global Single Dose Vial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 20. Global Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 21. Global Post-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global Post-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global Post-Exposure Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global Pre-Exposure Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Pre-Exposure Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Pre-Exposure Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 28. Global Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 38. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 50. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 51. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 52. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 53. Asia-Pacific Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 54. North America Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 55. North America Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 56. North America Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 57. North America Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 58. North America Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 59. North America Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 60. Latin America Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 61. Latin America Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 62. Latin America Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 63. Latin America Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 64. Latin America Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 65. Latin America Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 66. Europe Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 67. Europe Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 68. Europe Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 69. Europe Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 70. Europe Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 71. Europe Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 72. Middle East Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Middle East Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 74. Middle East Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 75. Middle East Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 76. Middle East Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 77. Middle East Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 78. Africa Hepatitis A Inactivated Vaccine Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Africa Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 80. Africa Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 81. Africa Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 82. Africa Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 83. Africa Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 84. Global Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 85. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 87. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 88. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 89. ASEAN Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 90. ASEAN Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 91. GCC Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. GCC Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 93. GCC Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 94. GCC Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 95. GCC Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 96. GCC Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 97. European Union Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 98. European Union Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 99. European Union Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 100. European Union Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 101. European Union Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 102. European Union Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 103. BRICS Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 104. BRICS Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 105. BRICS Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 106. BRICS Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 107. BRICS Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 108. BRICS Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 109. G7 Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 110. G7 Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 111. G7 Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 112. G7 Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 113. G7 Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 114. G7 Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. NATO Hepatitis A Inactivated Vaccine Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. NATO Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 117. NATO Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 118. NATO Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 119. NATO Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 120. NATO Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 121. Global Hepatitis A Inactivated Vaccine Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 122. United States Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 123. United States Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 124. United States Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 125. United States Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 126. United States Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 127. United States Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 128. Canada Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 129. Canada Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 130. Canada Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 131. Canada Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 132. Canada Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 133. Canada Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. Mexico Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 135. Mexico Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 136. Mexico Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 137. Mexico Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 138. Mexico Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 139. Mexico Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 140. Brazil Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 141. Brazil Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 142. Brazil Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 143. Brazil Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 144. Brazil Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 145. Brazil Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 146. United Kingdom Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 147. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 148. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 149. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 150. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 151. United Kingdom Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 152. Germany Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 153. Germany Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 154. Germany Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 155. Germany Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 156. Germany Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 157. Germany Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. France Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 159. France Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 160. France Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 161. France Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 162. France Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 163. France Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 164. Russia Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 165. Russia Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 166. Russia Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 167. Russia Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 168. Russia Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 169. Russia Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. Italy Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 171. Italy Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 172. Italy Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 173. Italy Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 174. Italy Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 175. Italy Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 176. Spain Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 177. Spain Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 178. Spain Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 179. Spain Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 180. Spain Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 181. Spain Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 182. China Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 183. China Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 184. China Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 185. China Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 186. China Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 187. China Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 188. India Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 189. India Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 190. India Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 191. India Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 192. India Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. India Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 194. Japan Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 195. Japan Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 196. Japan Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 197. Japan Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 198. Japan Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 199. Japan Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 200. Australia Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 201. Australia Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 202. Australia Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 203. Australia Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 204. Australia Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 205. Australia Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 206. South Korea Hepatitis A Inactivated Vaccine Market Size, 2017-2032 (USD Million)
  • TABLE 207. South Korea Hepatitis A Inactivated Vaccine Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 208. South Korea Hepatitis A Inactivated Vaccine Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 209. South Korea Hepatitis A Inactivated Vaccine Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 210. South Korea Hepatitis A Inactivated Vaccine Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 211. South Korea Hepatitis A Inactivated Vaccine Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 212. Global Hepatitis A Inactivated Vaccine Market Share, by Key Player, 2025
  • TABLE 213. Global Hepatitis A Inactivated Vaccine Market, Key Experts